PremiumThe FlyScynexis expects cash to fund operations into Q3 of 2026 SCYX Earnings this Week: How Will it Perform? Scynexis to present preclinical data on SCY-247 at ESCMID Meeting PremiumCompany AnnouncementsSCYNEXIS Advances Antifungal Treatments, Strengthens Financial Outlook SCYX Earnings Report this Week: Is It a Buy, Ahead of Earnings? Scynexis reports Q2 EPS (30c), consensus (20c) PremiumThe FlyScynexis announces presentation of data from fungerp candidate SCY-247 Scynexis to present preclinical data on SCY-247 Scynexis reports binding MOU with GSK for amendment to license agreement 
